Protagenic Therapeutics (PTIX) Insider Trading & Ownership $4.00 +0.06 (+1.52%) Closing price 04:00 PM EasternExtended Trading$3.99 -0.01 (-0.25%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Protagenic Therapeutics (NASDAQ:PTIX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage35.00%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$6,475.14Number OfInsiders Selling(Last 3 Years)0 Get PTIX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protagenic Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PTIX Insider Buying and Selling by Quarter Protagenic Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/12/2023Alexander K ArrowCFOBuy571$11.34$6,475.14 (Data available from 1/1/2013 forward) PTIX Insider Trading Activity - Frequently Asked Questions Who is on Protagenic Therapeutics's Insider Roster? The list of insiders at Protagenic Therapeutics includes Alexander K Arrow. Learn more on insiders at PTIX. What percentage of Protagenic Therapeutics stock is owned by insiders? 35.00% of Protagenic Therapeutics stock is owned by insiders. Learn more on PTIX's insider holdings. Which Protagenic Therapeutics insiders have been buying company stock? The following insider purchased PTIX shares in the last 24 months: Alexander K Arrow ($6,475.14). How much insider buying is happening at Protagenic Therapeutics? Insiders have purchased a total of 571 PTIX shares in the last 24 months for a total of $6,475.14 bought. Protagenic Therapeutics Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Co-Founder & Executive Chairman of the Board Dr. Alexander Kenneth Arrow C.F.A. (Age 53)M.D., CFO & Secretary Compensation: $150kDr. Andrew Slee Ph.D. (Age 74)Chief Operating Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., Chief Medical Officer & Director More Insider Trading Tools from MarketBeat Related Companies CalciMedica Insider Selling Cyclacel Pharmaceuticals Insider Selling Eagle Pharmaceuticals Insider Selling Tempest Therapeutics Insider Selling Cara Therapeutics Insider Selling Cyclo Therapeutics Insider Selling KALA BIO Insider Selling CASI Pharmaceuticals Insider Selling BioAtla Insider Selling Clene Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Meta's Institutional & Insider Data Fuels Bulls Despite DisparityTurbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears This page (NASDAQ:PTIX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
